Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Thermo Fisher Scientific Inc., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022 Dec 31, 2021 Oct 2, 2021 Jul 3, 2021 Apr 3, 2021 Dec 31, 2020 Sep 26, 2020 Jun 27, 2020 Mar 28, 2020 Dec 31, 2019 Sep 28, 2019 Jun 29, 2019 Mar 30, 2019
Net income 1,629 1,554 1,331 1,606 1,695 1,362 1,292 1,574 1,498 1,668 2,220 1,661 1,901 1,829 2,337 2,498 1,933 1,156 788 1,002 760 1,119 815
Depreciation of property, plant and equipment 290 277 285 276 269 270 253 256 244 236 250 217 205 211 198 191 161 157 149 148 141 142 133
Amortization of acquisition-related intangible assets 449 514 551 563 584 585 606 592 594 600 609 466 423 449 423 411 414 417 425 428 434 429 422
Change in deferred income taxes (400) (354) (253) (669) (303) (182) (146) (133) (261) (262) (339) (192) (148) (331) 24 (56) (178) (277) (41) 54 36 (286) (106)
Loss on early extinguishment of debt 26 570 197 184
Gain on sales of businesses 4 19 (505)
Stock-based compensation 68 84 70 61 67 74 76 75 77 77 78 77 51 51 51 51 52 47 46 43 42 52 44
Other non-cash expenses, net 100 101 54 163 111 149 181 81 152 58 233 (4) (19) 144 69 131 100 45 64 (39) 75 30 18
Changes in assets and liabilities, excluding the effects of acquisitions 30 (216) (787) 1,723 (9) (718) (1,533) 1,042 (367) (849) (875) (338) 237 (126) (1,321) 113 226 341 (1,075) 89 (390) 313 (677)
Adjustments to reconcile net income to net cash provided by operating activities 537 406 (80) 2,117 719 178 (563) 1,913 439 (140) (18) 796 749 398 (359) 841 775 730 (432) 911 357 175 (166)
Net cash provided by operating activities 2,166 1,960 1,251 3,723 2,414 1,540 729 3,487 1,937 1,528 2,202 2,457 2,650 2,227 1,978 3,339 2,708 1,886 356 1,913 1,117 1,294 649
Purchases of property, plant and equipment (272) (301) (347) (405) (332) (284) (458) (550) (547) (506) (640) (831) (524) (540) (628) (586) (366) (269) (253) (289) (216) (220) (201)
Proceeds from sale of property, plant and equipment 20 16 4 11 66 4 6 6 4 12 2 11 4 5 1 1 2 4 18 6 6 6
Proceeds from cross-currency interest rate swap interest settlements 92 47 64 34 1 33 2
Acquisitions, net of cash acquired (3,132) (909) (47) (2,704) 1 (40) (17,876) (94) (82) (1,343) (35) 1 (4) (156) (1) (1,685) (1)
Proceeds from sale of business, net of cash divested 2 1,126
Purchases of investments (287) (20) (1,758)
Other investing activities, net 1 5 7 (16) (7) (149) 12 19 (3) 75 8 4 (2) (4) (32) (6) 7 (7) 88 11 4 15
Net cash used in investing activities (3,578) (253) (2,030) (376) (1,181) (443) (3,142) (525) (545) (419) (670) (18,692) (616) (626) (1,998) (626) (365) (259) (260) (339) (198) (769) (181)
Net proceeds from issuance of debt (1) 1,205 2,476 3,466 3,193 15,015 3,122 1,279 2,185 5,638
Repayment of debt (1,107) (3,782) (1,000) (1,000) (375) (8,931) (2) (1) (2,804) (1) (710) (1) (1) (4,658) (1,699) (2) (1)
Proceeds from issuance of commercial paper 593 1,027 295 199 406 626 2,512 1 382 200 686 1,795 100
Repayments of commercial paper (494) (918) (523) (200) (2,231) (1,259) (66) (321) (886) (723) (1,068) (787)
Purchases of company common stock (3,000) (3,000) (1,000) (2,000) (2,000) (1,500) (750) (750)
Dividends paid (150) (149) (135) (136) (135) (135) (117) (117) (118) (117) (103) (103) (102) (103) (87) (87) (87) (87) (76) (76) (77) (76) (68)
Other financing activities, net 67 35 109 14 18 4 20 20 (32) 37 (34) (26) 22 28 41 39 6 54 (50) 18 (56) 41 81
Net cash provided by (used in) financing activities (1,190) (115) (1,821) (1,428) 1,855 (1,456) (2,593) 2,391 (151) (1,905) (3,145) 8,467 3,040 (76) (4,850) (49) (791) 1,180 619 (514) (1,869) 690 (1,425)
Exchange rate effect on cash 175 (14) 22 10 (73) 12 (31) 250 (212) (78) (99) 211 (61) (93) 137 102 181 20 (127) 57 (59) (29) (32)
Increase (decrease) in cash, cash equivalents and restricted cash (2,427) 1,578 (2,578) 1,929 3,015 (347) (5,037) 5,603 1,029 (874) (1,712) (7,557) 5,013 1,432 (4,733) 2,766 1,733 2,827 588 1,117 (1,009) 1,186 (989)

Based on: 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-26), 10-Q (reporting date: 2020-06-27), 10-Q (reporting date: 2020-03-28), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-28), 10-Q (reporting date: 2019-06-29), 10-Q (reporting date: 2019-03-30).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Thermo Fisher Scientific Inc. net cash provided by operating activities increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Net cash used in investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Thermo Fisher Scientific Inc. net cash used in investing activities increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Thermo Fisher Scientific Inc. net cash provided by (used in) financing activities increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024 not reaching Q1 2024 level.